Enanta Pharmaceuticals to Present at Upcoming Investor Conferences

Rhea-AI Summary

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that CEO Jay R. Luly will present at three virtual investor conferences. Key presentations include:

• H.C. Wainwright & Co. Global Life Sciences Conference on March 9, 2021
• 33rd Annual Roth Conference on March 15, 2021, discussing COVID-19 therapies
• Oppenheimer & Co. Healthcare Conference on March 16, 2021

Webcasts will be available on Enanta’s website, with replays archived for 90 days. Enanta specializes in small molecule drugs targeting viral infections and liver diseases.

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at three upcoming virtual investor conferences:

• H.C. Wainwright & Co. Global Life Sciences Conference: Corporate presentation available for on-demand viewing on Tuesday, March 9, 2021
• 33^rd Annual Roth Conference: Panel presentation “Therapies and Vaccines in the Fight Against COVID-19” on Monday, March 15, 2021 at 3:00 p.m. ET and corporate presentation available for on-demand viewing on Tuesday, March 9, 2021
• Oppenheimer & Co. 31^st Annual Healthcare Conference: Corporate presentation on Tuesday, March 16, 2021 at 8:00 a.m. ET

Webcasts of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of each webcast will be available following the presentations and will be archived for approximately 90 days.

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). Enanta is also conducting research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET^® (U.S.) and MAVIRET^® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005290/en/

FAQ

What virtual conferences will Enanta Pharmaceuticals present at in March 2021?

Enanta Pharmaceuticals will present at the H.C. Wainwright & Co. Global Life Sciences Conference on March 9, 2021, the 33rd Annual Roth Conference on March 15, 2021, and the Oppenheimer & Co. Healthcare Conference on March 16, 2021.

What topics will be covered in Enanta's presentations?

Enanta's presentations will focus on small molecule drugs for viral infections, with a specific panel on COVID-19 therapies during the Roth Conference.

Where can I access the webcasts of Enanta Pharmaceuticals' presentations?

Webcasts of Enanta Pharmaceuticals' presentations will be available on the 'Events and Presentations' section of their website, with replays archived for about 90 days.

What is Enanta Pharmaceuticals' focus area?

Enanta Pharmaceuticals focuses on developing small molecule drugs for viral infections and liver diseases, targeting conditions like RSV, HBV, and NASH.

How is Enanta Pharmaceuticals funded for its research?

Enanta's research and development activities are primarily funded by royalties from hepatitis C virus products developed in collaboration with AbbVie.